stocks logo

BPMC Valuation

Blueprint Medicines Corp
$
0.000
-129.46(-100.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

BPMC Relative Valuation

BPMC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BPMC is overvalued; if below, it's undervalued.

Historical Valuation

P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
24.40
P/B
Median3y
16.18
Median5y
11.41
-1.80
FCF Yield
Median3y
-9.91
Median5y
-6.03

Competitors Valuation Multiple

The average P/S ratio for BPMC's competitors is 8.03, providing a benchmark for relative valuation. Blueprint Medicines Corp Corp (BPMC) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 55.45%, this premium appears sustainable.

FAQ

arrow icon

Is Blueprint Medicines Corp (BPMC) currently overvalued or undervalued?

Blueprint Medicines Corp (BPMC) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -24.72. The fair price of Blueprint Medicines Corp (BPMC) is between to according to relative valuation methord.
arrow icon

What is Blueprint Medicines Corp (BPMC) fair value?

arrow icon

How does BPMC's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Blueprint Medicines Corp (BPMC) as of Jul 27 2025?

arrow icon

What is the current FCF Yield for Blueprint Medicines Corp (BPMC) as of Jul 27 2025?

arrow icon

What is the current Forward P/E ratio for Blueprint Medicines Corp (BPMC) as of Jul 27 2025?

arrow icon

What is the current Forward P/S ratio for Blueprint Medicines Corp (BPMC) as of Jul 27 2025?